PL2493466T3 - Nowe przeciwguzowe zastosowanie kabazytakselu - Google Patents

Nowe przeciwguzowe zastosowanie kabazytakselu

Info

Publication number: PL2493466T3
Authority: PL; Poland
Prior art keywords: cabazytaxel; tumble; application; new anti; new
Prior art date: 2009-10-29

Application number

PL10782039T

Other languages

English (en)

Inventor

Sunil Gupta

Original Assignee

Sanofi Mature Ip

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-10-29

Filing date

2010-10-27

Publication date

2021-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43567614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2493466(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-10-27 Application filed by Sanofi Mature Ip filed Critical Sanofi Mature Ip

2021-11-15 Publication of PL2493466T3 publication Critical patent/PL2493466T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Epoxy Compounds (AREA)

PL10782039T 2009-10-29 2010-10-27 Nowe przeciwguzowe zastosowanie kabazytakselu PL2493466T3 (pl)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US25616009P	2009-10-29	2009-10-29
US29390310P	2010-01-11	2010-01-11
US35588810P	2010-06-17	2010-06-17
US35583410P	2010-06-17	2010-06-17
US36992910P	2010-08-02	2010-08-02
US38393310P	2010-09-17	2010-09-17
US38996910P	2010-10-05	2010-10-05
EP10782039.1A EP2493466B1 (en)	2009-10-29	2010-10-27	Novel antitumoral use of cabazitaxel
PCT/IB2010/054866 WO2011051894A1 (en)	2009-10-29	2010-10-27	Novel antitumoral use of cabazitaxel

Publications (1)

Publication Number	Publication Date
PL2493466T3 true PL2493466T3 (pl)	2021-11-15

Family

ID=43567614

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL10782039T PL2493466T3 (pl)	2009-10-29	2010-10-27	Nowe przeciwguzowe zastosowanie kabazytakselu

Country Status (31)

Country	Link
US (8)	US8927592B2 (pl)
EP (1)	EP2493466B1 (pl)
JP (2)	JP5566466B2 (pl)
KR (1)	KR101712231B1 (pl)
CN (1)	CN102770131A (pl)
AR (1)	AR078824A1 (pl)
AU (4)	AU2010310986A1 (pl)
BR (1)	BR112012011457A2 (pl)
CA (1)	CA2779009A1 (pl)
CR (1)	CR20120204A (pl)
DK (1)	DK2493466T3 (pl)
EA (1)	EA024186B1 (pl)
EC (1)	ECSP12011836A (pl)
ES (1)	ES2862340T3 (pl)
GT (1)	GT201200123A (pl)
IL (3)	IL219443A0 (pl)
MA (1)	MA33767B1 (pl)
MX (1)	MX336339B (pl)
MY (1)	MY164086A (pl)
NI (1)	NI201200071A (pl)
PE (1)	PE20121429A1 (pl)
PH (1)	PH12012500848A1 (pl)
PL (1)	PL2493466T3 (pl)
PT (1)	PT2493466T (pl)
SG (1)	SG10201810928SA (pl)
SV (1)	SV2012004192A (pl)
TN (1)	TN2012000188A1 (pl)
TW (2)	TWI533866B (pl)
UY (1)	UY32987A (pl)
WO (1)	WO2011051894A1 (pl)
ZA (1)	ZA201203123B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2926551A1 (fr)	2008-01-17	2009-07-24	Aventis Pharma Sa	Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
US20120065255A1 (en) *	2009-10-19	2012-03-15	Nagesh Palepu	Cabazitaxel formulations and methods of preparing thereof
CN102770131A (zh)	2009-10-29	2012-11-07	安万特医药股份有限公司	卡巴他赛的新颖抗肿瘤用途
JP2014514306A (ja) *	2011-04-12	2014-06-19	プラス・ケミカルス・エスアー	固体形態のカバジタキセル及びその製造方法
CN102503913B (zh) *	2011-10-20	2014-03-26	江苏红豆杉生物科技股份有限公司	直接用于x射线单晶衍射分析的二甲氧基紫杉烷类化合物单晶晶体的制备方法
JP6025861B2 (ja) *	2011-12-13	2016-11-16	アベンティス・ファーマ・ソシエテ・アノニム	カバジタキセルの結晶形およびこれを調製するための方法
WO2013111157A1 (en) *	2012-01-03	2013-08-01	Shilpa Medicare Limited	Process for preparing amorphous cabazitaxel
CN104583189A (zh)	2012-07-31	2015-04-29	永信药品工业股份有限公司	非晶型的卡巴利他索
TW201438714A (zh) *	2013-03-04	2014-10-16	Aventis Pharma Sa	卡巴他賽（ｃａｂａｚｉｔａｘｅｌ）及其治療轉移性前列腺癌之用途
EP2815749A1 (en)	2013-06-20	2014-12-24	IP Gesellschaft für Management mbH	Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
PT3258931T (pt) *	2015-02-17	2020-09-23	Univ Erasmus Med Ct Rotterdam	Utilização do cabazitaxel no tratamento do cancro da próstata
EP3093014A1 (en)	2015-05-13	2016-11-16	Aventis Pharma S.A.	Cabazitaxel and its use for treating cancer
EP3509569A1 (en)	2016-09-07	2019-07-17	Cadila Healthcare Limited	Sterile injectable compositions comprising drug micelles
US10195214B2 (en)	2017-03-01	2019-02-05	Corcept Therapeutics, Inc.	Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
US20210088505A1 (en) *	2017-04-07	2021-03-25	La Jolla Institute For Allergy And Immunology	Unipotent Neutrophil Progenitor Cells, Methods of Preparation, and Uses Thereof
US20250017891A1 (en) *	2023-07-04	2025-01-16	Twi Pharmaceuticals, Inc.	Pharmaceutical composition comprising cabazitaxel prodrug-cyclodextrin inclusion complex, and applications thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2601675B1 (fr)	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US5005588A (en)	1989-10-13	1991-04-09	David Rubin	Method for increasing tumor sensitivity to chemotherapy
US5714512A (en)	1991-07-08	1998-02-03	Rhone-Poulenc Rorer, S.A.	Compositions containing taxane derivatives
US5750561A (en)	1991-07-08	1998-05-12	Rhone-Poulenc Rorer, S.A.	Compositions containing taxane derivatives
US5698582A (en)	1991-07-08	1997-12-16	Rhone-Poulenc Rorer S.A.	Compositions containing taxane derivatives
FR2698543B1 (fr)	1992-12-02	1994-12-30	Rhone Poulenc Rorer Sa	Nouvelles compositions à base de taxoides.
FR2698871B1 (fr)	1992-12-09	1995-02-24	Rhone Poulenc Rorer Sa	Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
ZA94128B (en)	1993-02-01	1994-08-19	Univ New York State Res Found	Process for the preparation of taxane derivatives and betalactam intermediates therefor
FR2732340B1 (fr)	1995-03-27	1997-04-30	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
MA23823A1 (fr)	1995-03-27	1996-10-01	Aventis Pharma Sa	Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US5847170A (en)	1995-03-27	1998-12-08	Rhone-Poulenc Rorer, S.A.	Taxoids, their preparation and pharmaceutical compositions containing them
US6372780B2 (en)	1995-03-27	2002-04-16	Aventis Pharma S.A.	Methods of treating cell lines expressing multidrug resistance P-glycoprotein
FR2745814B1 (fr)	1996-03-06	1998-04-03	Rhone Poulenc Rorer Sa	Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr)	1997-11-18	1999-12-17	Rhone Poulenc Rorer Sa	Procede de preparation de derives de la classe des taxoides
US6346543B1 (en)	1998-08-17	2002-02-12	Aventis Pharma S.A.	Use of a taxoid to treat abnormal cell proliferation in the brain
WO2000010547A2 (en)	1998-08-20	2000-03-02	Aventis Pharma S.A.	New use of taxoid derivatives
US6403634B1 (en)	1999-01-13	2002-06-11	Aventis Pharma S.A.	Use of taxoid derivatives
US20040126379A1 (en)	2002-08-21	2004-07-01	Boehringer Ingelheim International Gmbh	Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
SI1493556T1 (sl)	2003-07-02	2006-02-28	Scheuten Glasgroep Bv	Postopek za pripravo protipozarne zasteklitve
EP1498120A1 (en)	2003-07-18	2005-01-19	Aventis Pharma S.A.	Semi-solid formulations for the oral administration of taxoids
FR2859996B1 (fr) *	2003-09-19	2006-02-03	Aventis Pharma Sa	Solvat acetonique du dimethoxy docetaxel et son procede de preparation
GB0425854D0 (en)	2004-11-25	2004-12-29	Astrazeneca Ab	Therapeutic treatment
SG156625A1 (en)	2004-12-08	2009-11-26	Aventis Pharma Inc	Method for measuring resistance or sensitivity to docetaxel
EP1700596A1 (en)	2005-03-09	2006-09-13	Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V.	Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons
AR054215A1 (es)	2006-01-20	2007-06-13	Eriochem Sa	Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
FR2922107B1 (fr)	2007-10-10	2010-02-26	Aventis Pharma Sa	Nouvelles compositions a base de taxoides
FR2926551A1 (fr)	2008-01-17	2009-07-24	Aventis Pharma Sa	Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
EP2177630A1 (en) *	2008-10-02	2010-04-21	Institut Gustave Roussy	Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
US9427418B2 (en)	2009-02-23	2016-08-30	Gtx, Inc.	Estrogen receptor ligands and methods of use thereof
CN103932972A (zh)	2009-03-30	2014-07-23	天蓝制药公司	聚合物-药剂缀合物、颗粒、组合物和相关使用方法
FR2945211A1 (fr)	2009-05-06	2010-11-12	Sanofi Aventis	Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
US20110160159A1 (en)	2009-09-15	2011-06-30	John Ryan	Treatment of cancer
US7772274B1 (en)	2009-10-19	2010-08-10	Scidose, Llc	Docetaxel formulations with lipoic acid
CN102770131A (zh)	2009-10-29	2012-11-07	安万特医药股份有限公司	卡巴他赛的新颖抗肿瘤用途
ES2621613T3 (es)	2009-11-04	2017-07-04	Emcure Pharmaceuticals Limited	Un proceso mejorado para la preparación de derivados de taxano
AU2010321533A1 (en)	2009-11-23	2012-05-31	Cerulean Pharma Inc.	Cyclodextrin-based polymers for therapeutic delivery
WO2011124669A1 (en)	2010-04-08	2011-10-13	Institut Gustave Roussy	Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2011130317A2 (en)	2010-04-13	2011-10-20	Amplyx Pharmaceuticals Inc.	Therapeutic agents having reduced toxicity
AU2011239569B2 (en)	2010-04-16	2014-07-24	Baylor College Of Medicine	Method for treating solid tumors
EP3093014A1 (en)	2015-05-13	2016-11-16	Aventis Pharma S.A.	Cabazitaxel and its use for treating cancer
EP3808345A1 (en)	2019-10-15	2021-04-21	Sanofi Mature IP	Cabazitaxel in mcrpc patients previously treated with docetaxel and who failed a prior androgen signaling targeted inhibitor agent

2010
- 2010-10-27 CN CN2010800600528A patent/CN102770131A/zh active Pending
- 2010-10-27 MY MYPI2012001871A patent/MY164086A/en unknown
- 2010-10-27 CA CA2779009A patent/CA2779009A1/en not_active Abandoned
- 2010-10-27 EA EA201270606A patent/EA024186B1/ru not_active IP Right Cessation
- 2010-10-27 KR KR1020127013564A patent/KR101712231B1/ko active Active
- 2010-10-27 SG SG10201810928SA patent/SG10201810928SA/en unknown
- 2010-10-27 PE PE2012000581A patent/PE20121429A1/es not_active Application Discontinuation
- 2010-10-27 JP JP2012535996A patent/JP5566466B2/ja active Active
- 2010-10-27 AU AU2010310986A patent/AU2010310986A1/en not_active Abandoned
- 2010-10-27 EP EP10782039.1A patent/EP2493466B1/en active Active
- 2010-10-27 PL PL10782039T patent/PL2493466T3/pl unknown
- 2010-10-27 ES ES10782039T patent/ES2862340T3/es active Active
- 2010-10-27 PH PH1/2012/500848A patent/PH12012500848A1/en unknown
- 2010-10-27 DK DK10782039.1T patent/DK2493466T3/da active
- 2010-10-27 WO PCT/IB2010/054866 patent/WO2011051894A1/en not_active Ceased
- 2010-10-27 PT PT107820391T patent/PT2493466T/pt unknown
- 2010-10-27 BR BR112012011457A patent/BR112012011457A2/pt not_active Application Discontinuation
- 2010-10-27 MX MX2012005030A patent/MX336339B/es unknown
- 2010-10-29 AR ARP100103990 patent/AR078824A1/es unknown
- 2010-10-29 UY UY32987A patent/UY32987A/es unknown
- 2010-10-29 TW TW099137327A patent/TWI533866B/zh active
- 2010-10-29 TW TW104143630A patent/TWI654975B/zh active
2012
- 2012-04-25 CR CR20120204A patent/CR20120204A/es unknown
- 2012-04-25 TN TNP2012000188A patent/TN2012000188A1/en unknown
- 2012-04-25 IL IL219443A patent/IL219443A0/en unknown
- 2012-04-26 US US13/456,720 patent/US8927592B2/en active Active
- 2012-04-26 GT GT201200123A patent/GT201200123A/es unknown
- 2012-04-27 EC ECSP12011836 patent/ECSP12011836A/es unknown
- 2012-04-27 SV SV2012004192A patent/SV2012004192A/es unknown
- 2012-04-27 NI NI201200071A patent/NI201200071A/es unknown
- 2012-04-30 ZA ZA2012/03123A patent/ZA201203123B/en unknown
- 2012-05-25 MA MA34898A patent/MA33767B1/fr unknown
2014
- 2014-06-16 JP JP2014123108A patent/JP6182510B2/ja active Active
- 2014-12-18 US US14/575,578 patent/US20150118182A1/en not_active Abandoned
- 2014-12-18 US US14/575,566 patent/US20150104411A1/en not_active Abandoned
2016
- 2016-02-01 AU AU2016200598A patent/AU2016200598A1/en not_active Abandoned
2017
- 2017-01-24 IL IL250254A patent/IL250254A0/en unknown
- 2017-06-20 US US15/627,962 patent/US10583110B2/en active Active
- 2017-09-25 AU AU2017232227A patent/AU2017232227B2/en not_active Ceased
2019
- 2019-01-18 US US16/251,143 patent/US20190151278A1/en not_active Abandoned
- 2019-05-20 AU AU2019203514A patent/AU2019203514A1/en not_active Abandoned
- 2019-06-23 IL IL267583A patent/IL267583A/en unknown
2020
- 2020-01-15 US US16/743,411 patent/US10716777B2/en active Active
- 2020-07-17 US US16/931,802 patent/US20210169843A1/en not_active Abandoned
2023
- 2023-07-20 US US18/224,122 patent/US12453712B2/en active Active

Also Published As

Publication number	Publication date
US20190151278A1 (en)	2019-05-23
US20200155497A1 (en)	2020-05-21
MX2012005030A (es)	2012-12-05
PT2493466T (pt)	2021-03-29
SV2012004192A (es)	2012-08-23
US8927592B2 (en)	2015-01-06
TWI533866B (zh)	2016-05-21
AR078824A1 (es)	2011-12-07
MY164086A (en)	2017-11-30
JP2014196323A (ja)	2014-10-16
JP6182510B2 (ja)	2017-08-16
KR20120093986A (ko)	2012-08-23
NI201200071A (es)	2012-08-20
DK2493466T3 (da)	2021-04-26
CA2779009A1 (en)	2011-05-05
TWI654975B (zh)	2019-04-01
EP2493466B1 (en)	2021-03-10
SG10201810928SA (en)	2019-01-30
US12453712B2 (en)	2025-10-28
AU2019203514A1 (en)	2019-06-06
US20210169843A1 (en)	2021-06-10
JP5566466B2 (ja)	2014-08-06
US20150118182A1 (en)	2015-04-30
PE20121429A1 (es)	2012-11-06
EP2493466A1 (en)	2012-09-05
US10583110B2 (en)	2020-03-10
AU2010310986A1 (en)	2012-06-14
PH12012500848A1 (en)	2016-02-08
IL267583A (en)	2019-08-29
TW201611831A (en)	2016-04-01
TN2012000188A1 (en)	2013-12-12
CN102770131A (zh)	2012-11-07
ES2862340T3 (es)	2021-10-07
EA024186B1 (ru)	2016-08-31
AU2016200598A1 (en)	2016-02-25
ZA201203123B (en)	2013-06-26
MX336339B (es)	2016-01-14
BR112012011457A2 (pt)	2016-05-03
UY32987A (es)	2011-05-31
KR101712231B1 (ko)	2017-03-03
CR20120204A (es)	2012-07-04
IL219443A0 (en)	2012-06-28
IL250254A0 (en)	2017-03-30
US20150104411A1 (en)	2015-04-16
EA201270606A1 (ru)	2013-01-30
ECSP12011836A (es)	2012-07-31
AU2017232227B2 (en)	2019-06-06
US20120301425A1 (en)	2012-11-29
TW201127374A (en)	2011-08-16
US10716777B2 (en)	2020-07-21
AU2017232227A1 (en)	2017-10-12
WO2011051894A1 (en)	2011-05-05
US20180125810A1 (en)	2018-05-10
JP2013509394A (ja)	2013-03-14
US20240139146A1 (en)	2024-05-02
MA33767B1 (fr)	2012-11-01
GT201200123A (es)	2013-11-07

Publication	Publication Date	Title
HUS1900001I1 (hu)	2019-01-28	Transztiretin expressziójának módosítása
PL2493466T3 (pl)	2021-11-15	Nowe przeciwguzowe zastosowanie kabazytakselu
SMT201600075B (it)	2016-04-29	Composto di diamminocarbossammide eterociclica
DOP2012000114A (es)	2012-08-15	Inhibidor bromodominio de benzodiazepina
IL225867B (en)	2018-07-31	Coelenterazine substrates
EP2414948A4 (en)	2012-12-05	APPLICATION SHARING
PT2506716T (pt)	2017-08-24	Novos compostos tricíclicos
EP2518066A4 (en)	2013-07-03	NOVEL THROMBOCYTE AGGREGATION INHIBITOR
BR112012000657A2 (pt)	2016-11-16	novos azabicilohexanos
FI20095529L (fi)	2010-11-13	Probioottien uusi käyttö
EP2349335A4 (en)	2012-02-08	LEVETIRACETAM IMMUNOASSAYS
UY33156A (es)	2011-07-29	Nuevos compuestos tienopirrol
DK2453858T3 (da)	2014-11-03	Fremgangsmåde
SMT201500268B (it)	2016-01-08	Derivato di 5-idrossipirimidin-4-carbossammide
LT2506840T (lt)	2021-06-25	Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
DOP2011000348A (es)	2012-01-15	Construcciones casb7439
EP2629616A4 (en)	2014-03-26	SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER
DK2173197T3 (da)	2019-09-23	Fremgangsmåde
EP2595966A4 (en)	2015-12-09	SYNTHESIS OF CYCLOPENTACHINAZOLINES
IT1400080B1 (it)	2013-05-17	Disposizione di esca
FR2956419B1 (fr)	2015-01-16	Elements de construction calorifuges
FR2955136B1 (fr)	2012-01-20	Arret de vantail
FI9141U1 (fi)	2011-03-15	Apuväline
UY33133A (es)	2011-07-29	Nuevos derivados de piridazina
UA21042S (uk)	2010-10-25	Комплект бланків